Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HUA MEDICINE
華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(S c C de: 2552)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**B a d**") of directors (the "**D ec** ") of Hua Medicine (the "**C a** ") hereby announces that Mr. Yiu Leung Andy CHEUNG ("**M . C e** ") has been appointed as an independent non-executive Director with effect from January 1, 2023.

The biographical details of Mr. Cheung are set out below:

M . C e , aged 63, has been appointed as an independent non-executive Director with such appointment to take effect from January 1, 2023. He is primarily responsible for supervising and providing independent view to the Board. Mr. Cheung will also serve as the chairman of the audit committee of the Board (the "**A d C ee**") with effect from January 1, 2023, replacing Mr. Walter Teh-Ming KWAUK following his unfortunate passing away in November 2022.

Mr. Cheung has over 30 years of professional accounting and auditing experience. He has been serving as an independent non-executive director and the chairman of the audit committee of JW (Cayman) Therapeutics Co. Ltd, a company listed on The Stock Exchange of Hong Kong Limited (the "**S c E c a e**") (stock code: 2126), since October 2020. He has also been serving as an independent director and the chairman of the audit committee of Adagene Inc., a company listed on NASDAQ Stock Exchange in the United States (stock code: ADAG), since February 2021.

CHANGE IN COMPOSITION OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

The Board hereby announces that the following change in composition of the Board committees:

(i) following the appointment of Mr. Cheung as an independent non-executive Director, he has also been appointed as a chairman of the Audit Committee with effect from January 1, 2023; and

(ii) Mr. Yiu Wa Alec TSUI, an independent non-executive Director, has been appointed as a member of the Remuneration Committee with effect from January 1, 2023.

COMPLIANCE OF LISTING RULES

Reference is made to the announcement of the Company dated November 24, 2022 in relation to the passing away of Mr. Walter Teh-Ming KWAUK, a former independent non-executive Director and the former chairman of the Audit Committee.

Following the appointment of Mr. Cheung with effect from January 1, 2023, the Company has fully complied with the requirements as set out in Rules 3.10(2) and 3.21 of the Listing Rules.

By Order of the Board
D. L Ce
Chief Executive Officer and Executive Director

Hong Kong, December 30, 2022

As of the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Ms. Wei Zhao as non-executive Directors; and Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.